Theravance Biopharma (TBPH) Prepaid Assets (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Prepaid Assets of $7.4 million for Q1 2026, up 82.05% year-over-year from $4.1 million in Q1 2025, and down 2.38% quarter-over-quarter from $7.6 million in Q4 2025.
Theravance Biopharma (TBPH) Prepaid Assets (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Prepaid Assets for 14 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 82.05% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (up 82.05% YoY), while the FY2025 annual figure was $7.6 million, up 76.85% from the prior year.
- Prepaid Assets slipped to $7.4 million in Q1 2026 per TBPH's latest filing, from $7.6 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $11.6 million in Q4 2023 and bottomed at $4.1 million in Q1 2025.
- Historically, Prepaid Assets has averaged $7.0 million across 5 years, with a median of $7.4 million in 2026.
- Annual changes were most pronounced in 2024 — Prepaid Assets sank 63.14% — and 2026, when it soared 82.05%.
- Theravance Biopharma's Prepaid Assets stood at $7.7 million in 2022, then soared by 51.04% to $11.6 million in 2023, then tumbled by 63.14% to $4.3 million in 2024, then jumped by 76.85% to $7.6 million in 2025, then decreased by 2.38% to $7.4 million in 2026.
- Business Quant data shows TBPH's Prepaid Assets at $7.4 million in Q1 2026, $7.6 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.62 Mn |
| Mar 31, 2026 | 7.38 Mn |
| Dec 31, 2025 | 7.56 Mn |
| Sep 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 5.57 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Sep 30, 2024 | 7.68 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Dec 31, 2023 | 11.60 Mn |
| Sep 30, 2023 | 9.00 Mn |
| Jun 30, 2023 | 7.78 Mn |
| Mar 31, 2023 | 6.28 Mn |
| Dec 31, 2022 | 7.68 Mn |
| Sep 30, 2022 | 8.13 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 4.54 Mn |
| Dec 31, 2021 | 8.56 Mn |
| Sep 30, 2021 | 9.94 Mn |